 |
0 Products |  |
0 Diseases | | 0 Products |
|
0 Trials |  |
0 News |  |
- ||| MesenCure (adipose tissue derived activated mesenchymal stromal cells) / Wize Pharma, Bonus BioGroup
Trial completion, Enrollment change: Safety and the Efficacy of MesenCure for the Treatment of Pulmonary Manifestations of COVID-19 (clinicaltrials.gov) - Oct 6, 2023
P1/2, N=50, Completed, Sponsor: BonusBio Group Ltd
Recruiting --> Completed | N=35 --> 50
- |||| MesenCure (adipose tissue derived activated mesenchymal stromal cells) / Wize Pharma, Bonus BioGroup
Trial completion date, Trial primary completion date: A Controlled Study to Evaluate the Efficacy of Allogeneic MesenCure for the Treatment of Patients With ARDS (clinicaltrials.gov) - Oct 2, 2023
P3, N=300, Not yet recruiting, Sponsor: BonusBio Group Ltd
Recruiting --> Completed | N=35 --> 50 Trial completion date: Jul 2024 --> Jul 2026 | Trial primary completion date: Dec 2023 --> Jun 2026
- |||||||||| MesenCure (adipose tissue derived activated mesenchymal stromal cells) / Wize Pharma, Bonus BioGroup
New P3 trial: A Controlled Study to Evaluate the Efficacy of Allogeneic MesenCure for the Treatment of Patients With ARDS (clinicaltrials.gov) - Aug 11, 2022
P3, N=300, Not yet recruiting, Sponsor: BonusBio Group Ltd
- MesenCure (adipose tissue derived activated mesenchymal stromal cells) / Wize Pharma, Bonus BioGroup
Possible Divergent Local and Peripheral Immunological Effects of Low-Dose Mesencure, an Enhanced Mesenchymal Cell Therapy, May Contribute to Its Success in Treating Severe Covid-19 Patients (GWCC - Hall B5, Level 1) - Nov 5, 2021 - Abstract #ASH2021ASH_3786;
Further research is inevitably required into the mechanism behind this phenomenon. However, our results indicate MesenCure’s potential in relieving local inflammation while giving the patient a fighting chance against viremia.
- || MesenCure (adipose tissue derived activated mesenchymal stromal cells) / Wize Pharma, Bonus BioGroup
Enrollment open: Safety and the Efficacy of MesenCure for the Treatment of Pulmonary Manifestations of COVID-19 (clinicaltrials.gov) - Jan 21, 2021
P1/2, N=35, Recruiting, Sponsor: BonusBio Group Ltd
However, our results indicate MesenCure’s potential in relieving local inflammation while giving the patient a fighting chance against viremia. Not yet recruiting --> Recruiting
- || MesenCure (adipose tissue derived activated mesenchymal stromal cells) / Wize Pharma, Bonus BioGroup
New P1/2 trial: Safety and the Efficacy of MesenCure for the Treatment of Pulmonary Manifestations of COVID-19 (clinicaltrials.gov) - Jan 19, 2021
P1/2, N=35, Not yet recruiting, Sponsor: BonusBio Group Ltd